CYYNF: AI 评分 54/100 — AI 分析 (4月 2026)

Cynata Therapeutics Limited is an Australian biotechnology company focused on developing and commercializing its Cymerus mesenchymal stem cell technology for various therapeutic applications. Their lead product, CYP-001, targets graft-versus-host disease, while other candidates address osteoarthritis and diabetic wounds.

Key Facts: AI Score: 54/100 Sector: Healthcare

公司概况

概要：

Cynata Therapeutics Limited, an Australian biotech firm, leverages its proprietary Cymerus mesenchymal stem cell technology to develop therapies for graft-versus-host disease, osteoarthritis, and diabetic wounds. With a strategic partnership with Fujifilm, Cynata aims to provide clinical and commercial manufacturing for its cell-based products, positioning itself in the regenerative medicine sector.

CYYNF是做什么的？

Cynata Therapeutics Limited, founded in 2003 and based in Cremorne, Australia, is a biotechnology company dedicated to developing and commercializing a proprietary mesenchymal stem cell (MSC) technology known as Cymerus. This technology aims to address critical unmet medical needs through regenerative medicine. The company's journey began as Eco Quest Limited before rebranding to Cynata Therapeutics in October 2013, marking a strategic shift towards therapeutic development. Cynata's lead product candidate, CYP-001, has completed Phase I clinical trials for treating graft-versus-host disease (GvHD), a severe complication following stem cell transplantation. The company is also advancing CYP-004, currently in Phase III clinical trials, for the treatment of osteoarthritis, a prevalent and debilitating joint condition. Additionally, Cynata is developing CYP-006TK, a novel polymer-coated silicon wound dressing designed for diabetic wounds, addressing the challenges of impaired healing in diabetic patients. Beyond these core programs, Cynata is exploring the potential of its Cymerus technology in various other indications, including asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation, showcasing the versatility of its platform. A key strategic partnership with Fujifilm supports the clinical and commercial manufacturing and supply of Cynata's Cymerus-based therapeutic products, ensuring scalability and reliability in production.

CYYNF的投资论点是什么？

Cynata Therapeutics presents a compelling investment thesis centered on its Cymerus mesenchymal stem cell technology. The Phase III trial for CYP-004 in osteoarthritis represents a near-term value driver, with positive results potentially leading to regulatory approval and commercialization. The company's strategic partnership with Fujifilm provides a robust manufacturing foundation. Cynata's diversified pipeline, targeting indications like GvHD and diabetic wounds, offers multiple avenues for growth. With a market capitalization of $0.05 billion and a high gross margin of 253.3%, Cynata demonstrates financial efficiency. However, investors should be aware of the risks associated with clinical trial outcomes and regulatory hurdles, which could impact the stock's performance. The company's negative P/E ratio of -9.03 indicates it is not currently profitable.

CYYNF在哪个行业运营？

Cynata Therapeutics operates within the rapidly evolving biotechnology industry, specifically focusing on regenerative medicine and stem cell therapies. The market for stem cell therapies is projected to reach billions of dollars by 2030, driven by the increasing prevalence of chronic diseases and the demand for innovative treatments. The competitive landscape includes companies like CBSTF (Caladrius Biosciences), DSOL (Direxis Surgical), DTCFF (DermTech), MDDVF (Medexus Pharmaceuticals), and MMIRF (MIMEDX Group), each pursuing different approaches within the regenerative medicine space. Cynata's Cymerus technology offers a unique allogeneic approach, potentially providing scalability and cost-effectiveness advantages over autologous cell therapies.

Biotechnology

Healthcare

CYYNF有哪些增长机遇？

Osteoarthritis Treatment (CYP-004): The global osteoarthritis market is substantial, projected to reach $13.4 billion by 2028. Cynata's CYP-004, currently in Phase III trials, targets this large market. Positive trial results and subsequent regulatory approval could drive significant revenue growth. The timeline for potential commercialization is estimated within the next 2-3 years, assuming successful trial outcomes and regulatory clearance. Cynata's competitive advantage lies in its allogeneic cell therapy approach, which could offer a more scalable and cost-effective solution compared to existing treatments.
Graft-versus-Host Disease (CYP-001): Graft-versus-host disease (GvHD) represents a significant unmet medical need, particularly in patients undergoing hematopoietic stem cell transplantation. Cynata's CYP-001, having completed Phase I trials, targets this indication. The market for GvHD treatments is growing, driven by increasing transplantation procedures. Successful development and commercialization of CYP-001 could provide a valuable revenue stream for Cynata. The timeline for potential market entry is estimated within the next 3-5 years, contingent on further clinical development and regulatory approvals.
Diabetic Wound Care (CYP-006TK): Diabetic wounds pose a significant challenge due to impaired healing capabilities. Cynata's CYP-006TK, a novel polymer-coated silicon wound dressing, aims to address this issue. The diabetic wound care market is expanding, fueled by the rising prevalence of diabetes. Successful development and commercialization of CYP-006TK could offer a valuable addition to Cynata's product portfolio. The timeline for potential market entry is estimated within the next 2-4 years, pending further development and regulatory clearances.
Strategic Partnerships: Cynata's strategic partnership with Fujifilm provides a robust foundation for clinical and commercial manufacturing of its Cymerus-based products. This collaboration ensures scalability and reliability in production, which is crucial for meeting potential market demand. Leveraging Fujifilm's expertise and infrastructure can accelerate Cynata's growth trajectory and reduce manufacturing-related risks. The ongoing partnership strengthens Cynata's competitive position in the regenerative medicine space.
Expansion into New Therapeutic Areas: Cynata is exploring the potential of its Cymerus technology in various other indications, including asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. This diversified approach offers multiple avenues for growth and reduces the company's reliance on a single product or indication. Successful expansion into these new therapeutic areas could significantly enhance Cynata's long-term growth prospects.

Market Cap of $0.05 billion indicates a small-cap biotechnology company.
P/E ratio of -9.03 reflects current lack of profitability, common in early-stage biotech firms.
Profit Margin of 9887.9% suggests potential for high profitability upon commercialization of successful products.
Gross Margin of 253.3% highlights efficient cost management in product development.
Beta of 1.04 indicates the stock's volatility is similar to the overall market.

CYYNF提供哪些产品和服务？

Develops mesenchymal stem cell (MSC) technology under the Cymerus brand.
Focuses on therapeutic applications for human diseases.
Conducts clinical trials for product candidates.
Partners with Fujifilm for manufacturing and supply of Cymerus products.
Targets graft-versus-host disease (GvHD) with CYP-001.
Develops CYP-004 for the treatment of osteoarthritis.
Creates CYP-006TK for diabetic wound care.
Explores treatments for asthma, heart attack, and other diseases.

CYYNF如何赚钱？

Develops and patents mesenchymal stem cell (MSC) technology.
Out-licenses technology or partners with other companies for commercialization.
Generates revenue through milestone payments and royalties from partnered products.
Conducts internal research and development to expand the application of its Cymerus technology.

Patients suffering from graft-versus-host disease (GvHD).
Patients with osteoarthritis.
Patients with diabetic wounds.
Pharmaceutical companies seeking to license or partner on stem cell therapies.

Proprietary Cymerus technology platform for MSC production.
Strong patent portfolio protecting its MSC technology.
Strategic partnership with Fujifilm for manufacturing and supply.
Clinical data supporting the safety and efficacy of its product candidates.

什么因素可能推动CYYNF股价上涨？

Upcoming: Phase III clinical trial results for CYP-004 in osteoarthritis.
Upcoming: Potential regulatory approvals for CYP-001 or CYP-004.
Ongoing: Expansion of the Cymerus technology into new therapeutic areas.
Ongoing: Strategic partnerships and collaborations.
Ongoing: Publication of clinical data in peer-reviewed journals.

CYYNF的主要风险是什么？

Potential: Clinical trial failures.
Potential: Regulatory setbacks.
Potential: Competition from established therapies.
Potential: Economic downturns.
Ongoing: Limited financial resources.

CYYNF的核心优势是什么？

Proprietary Cymerus technology platform.
Strategic partnership with Fujifilm.
Diversified pipeline of product candidates.
Strong intellectual property protection.

CYYNF的劣势是什么？

Limited financial resources.
Dependence on clinical trial outcomes.
Regulatory hurdles for stem cell therapies.
Competition from larger biotechnology companies.

CYYNF有哪些机遇？

Expanding into new therapeutic areas.
Securing additional partnerships and collaborations.
Obtaining regulatory approvals for its product candidates.
Increasing awareness of its Cymerus technology.

CYYNF面临哪些威胁？

Clinical trial failures.
Regulatory setbacks.
Competition from established therapies.
Economic downturns.

CYYNF的竞争对手是谁？

Caladrius Biosciences — Focuses on developing cell therapies for autoimmune and cardiovascular diseases. — (CBSTF)
Direxis Surgical — Develops and commercializes medical devices for minimally invasive surgery. — (DSOL)
DermTech — Develops and markets genomic tests for skin cancer. — (DTCFF)
Medexus Pharmaceuticals — Acquires and commercializes niche pharmaceutical products. — (MDDVF)
MIMEDX Group — Develops and markets regenerative biomaterials for various applications. — (MMIRF)

Key Metrics

MoonshotScore: 54/100

Company Profile

CEO: Kilian Kelly
Headquarters: Cremorne, AU
Founded: 2015

AI Insight

AI analysis pending for CYYNF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Cynata Therapeutics Limited do?

Cynata Therapeutics Limited is an Australian biotechnology company focused on developing and commercializing therapeutic stem cell technologies. Their core technology, Cymerus, allows for the mass production of mesenchymal stem cells (MSCs) for various therapeutic applications. The company's primary focus is on developing treatments for diseases with high unmet needs, such as graft-versus-host disease (GvHD) and osteoarthritis, using their proprietary MSCs. Cynata aims to provide scalable and cost-effective cell therapies through its innovative Cymerus platform and strategic partnerships.

What do analysts say about CYYNF stock?

As of 2026-03-16, formal analyst ratings for CYYNF may be limited due to its OTC listing and smaller market capitalization. However, the company's potential lies in its Cymerus technology and clinical trial progress. Investors should monitor key valuation metrics such as market capitalization ($0.05B), profit margin (9887.9%), and gross margin (253.3%) to assess the company's financial health. Growth considerations include the successful completion of clinical trials and regulatory approvals for its lead product candidates. The negative P/E ratio (-9.03) indicates that the company is not currently profitable.

What are the main risks for CYYNF?

Investing in Cynata Therapeutics carries inherent risks associated with biotechnology companies, including clinical trial failures, regulatory hurdles, and competition from established therapies. The company's reliance on its Cymerus technology and the success of its clinical programs makes it vulnerable to setbacks in research and development. Additionally, as an OTC-listed stock, CYYNF faces risks related to liquidity, transparency, and regulatory oversight. Financial constraints and the need for additional funding may also pose challenges to the company's long-term growth.